Rezo Therapeutics

Rezo Therapeutics is a San Francisco-based biotechnology company that builds comprehensive maps of molecular disease networks in order to identify novel, druggable targets for precision therapeutics. Its "Sequence to Systems to Drugs" (SSD) platform integrates proteomics, genetics, structural biology, chemistry, and bioinformatics, combined with computational methods and artificial intelligence, to characterize disease-causing protein-protein, genetic, and biochemical interactions that the company says are difficult to detect with siloed, conventional approaches.

The platform is based on technology originating at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco. Rezo's initial therapeutic focus is solid tumor oncology, where it works to determine how mutations rewire cancer-driving networks in order to uncover tumor-specific targets, guide biomarker discovery for patient stratification, and develop mutation- and allele-specific precision medicines. The company has stated plans to expand into additional therapeutic areas through collaborations and partnerships. Its disease-specific maps are intended to support multiple treatment modalities, including small molecules that modulate protein activity.

Founding story

Rezo was founded by scientists associated with UCSF's Quantitative Biosciences Institute. Nevan Krogan, Ph.D., a UCSF professor, QBI director, and Gladstone Institutes senior investigator, developed the underlying integrated disease network mapping technology and served as co-founder and, at launch, chief executive officer. Additional co-founders named at launch include Kevan Shokat, Ph.D. (UCSF professor and HHMI investigator, known for work on KRAS-targeting chemistry), Sourav Bandyopadhyay, Ph.D. (UCSF professor and co-founder/chief scientific officer at launch), Natalia Jura, Ph.D. (UCSF professor and QBI associate director), George Scangos, Ph.D. (co-founder and board chair), and Norbert Bischofberger, Ph.D. (co-founder and board member). One third-party profile also lists Jacqueline Fabius among the co-founders and states the company was co-founded in 2022 by UCSF scientists.

Business model

Rezo operates as a therapeutics discovery and development company, using its proprietary platform to generate an internal pipeline of precision medicines rather than selling software or services. The company has stated it intends to explore additional therapeutic areas through collaborations and partnerships, indicating potential partnered development alongside proprietary programs.

No revenue is reported in the available sources; a financial data provider profile shows no disclosed revenue, EBITDA, or valuation figures for 2020-2024.

Traction

Disclosed traction consists primarily of the $78 million Series A at launch, assembly of a leadership team drawn from Intellia, Spark, Pfizer, Nurix, Dynavax, Merck, Octant, and Maze Therapeutics, and inclusion in BioSpace's 2024 lists of promising new biopharma companies. No clinical-stage programs, partnerships, or revenue figures are disclosed in the sources.

Latest developments

The most recent disclosed development is the appointment of Derek Hicks as chief executive officer, announced August 13, 2025. The company's website continues to advertise open roles.